Our expert for hiPSC derived cardiac cells, and cell-based assays & services for drug safety and efficacy screenings
Efficient assessment of drug safety and toxicity can be a complex and time consuming matter.
High quality – our safety pharmacology experts perform the studies on validated platforms
Save time - no assay optimization and data analysis needed – let our experts do this for you
Reliable – assays are based on fully functional and validated hiPSC-derived cardiomyocytes
Versatile – we offer a broad range of optimized assays on various platforms
Flexible – we will make sure to meet your specific needs
An acute MEA analysis
Delivers an acute cardiac safety profile of your compounds following the current protocols of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative for microelectrode arrays (MEA) analysis.
A longer-term MEA and impedance analysis
A (electro)physiological assessment of the potentially longer-term (0-48 hours) toxic effects of your compounds on hiPSC-derived cardiomyocytes as measured by a combination of MEA and impedance.
A multiplex of MEA, impedance and structural toxicity analysis
A multiparametric approach to deliver an extensive cardiotoxicity profile of your compounds. This service includes an analysis by impedance (contractility), microelectrode array (electrophysiology) and biomarker (e.g. Troponin I) release (structural).
A longer-term impedance analysis
Delivers a cost-effective, long-term cardiac safety profile based on label-free impedance analysis. Ideal for screening large numbers of compounds.
Industry’s first true contractile force measurement
Provides true force measurement to study the effect of drug candidates on the contractility and force-frequency relationships of hiPSC-derived cardiomyocyte.
A calcium-flux analysis
High-throughput screening of acute drug effects on cardiomyocyte electrophysiology by analyzing the intracellular calcium transients.
A structural toxicity analysis
Delivers a structural cardiotoxicity profile of your compounds based on the release of the cardiac specific biomarker Troponin I by hiPSC-derived cardiomyocytes.